Insights into Polycystic Kidney Disease
Pathogenesis

Travere Therapeutics, a mid-sized rare disease-focused biotechnology company with a strong presence in nephrology is looking for academic partners to support its discovery and development efforts. Specifically, Travere Therapeutics is exploring Polycystic Kidney Disease (PKD) and seeks potential research collaborations with laboratories focusing on Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Autosomal Recessive Polycystic Kidney Disease (ARPKD).

Approaches of Interest

- Insights into the disease pathogenesis and mechanistic pathways involved in different forms of PKD
- Research and technology that may provide a basis for conceiving and developing new treatment options
- Technologies that have been adapted to target and/or correct the cells and processes underlying the PKD pathology
- Drug delivery methods targeting the kidney e.g. viral particles, lipid nanoparticles
- All types of therapeutic modalities are of interest
- Biomarkers related to PKD

Out of Scope

- Drug repurposing
- Diagnostics
- Underlying conditions associated with PKD e.g. high blood pressure

Stage of Development

Travere Therapeutics is interested in opportunities ranging from inception to clinical phase II stages. Preference will be given to opportunities with validation e.g. in vitro and/or in vivo proof of concept studies in disease relevant models, evidence of novel mechanisms in PKD.

Jurisdictions of Interest: Europe, North America, South and Central America, Australia, New Zealand.

Submission Information: Submission of one-page, 200-300 word briefs are encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Potential Collaborations for Academics: Travere Therapeutics is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licencing, consulting, project funding and research collaborations.